These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 27200753)

  • 1. Proton Pump Inhibitors In South Africa: Role Of Branded Generics.
    Truter I
    Value Health; 2014 Nov; 17(7):A364. PubMed ID: 27200753
    [No Abstract]   [Full Text] [Related]  

  • 2. [Me too's and generics].
    Gysling E
    Praxis (Bern 1994); 1999 Apr; 88(16):709-12. PubMed ID: 10355336
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Generics: what is the role of registration authorities.
    Versantvoort C; Maliepaard M; Lekkerkerker F
    Neth J Med; 2008 Feb; 66(2):62-6. PubMed ID: 18292608
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imperative to consider multiple initiatives to maximize prescribing efficiency from generic availability: case history from Abu Dhabi.
    Abuelkhair M; Abdu S; Godman B; Fahmy S; Malmström RE; Gustafsson LL
    Expert Rev Pharmacoecon Outcomes Res; 2012 Feb; 12(1):115-24. PubMed ID: 22280201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pantoprazole: a proton pump inhibitor with oral and intravenous formulations.
    Devault KR
    Expert Rev Gastroenterol Hepatol; 2007 Dec; 1(2):197-205. PubMed ID: 19072410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quality and efficiency of statin prescribing across countries with a special focus on South Africa: findings and future implications.
    Godman B; Bishop I; Campbell SM; Malmström RE; Truter I
    Expert Rev Pharmacoecon Outcomes Res; 2015 Apr; 15(2):323-30. PubMed ID: 25338546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Compliance after switching from branded to generic statins.
    Romanelli RJ; Jukes T; Segal JB
    Pharmacoepidemiol Drug Saf; 2014 Oct; 23(10):1093-100. PubMed ID: 24817435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Psychiatrists' decision making between branded and generic drugs.
    Hamann J; Mendel R; Kissling W; Leucht S
    Eur Neuropsychopharmacol; 2013 Jul; 23(7):686-90. PubMed ID: 23021566
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rabeprazole: the role of proton pump inhibitors in Helicobacter pylori eradication.
    Sharara AI
    Expert Rev Anti Infect Ther; 2005 Dec; 3(6):863-70. PubMed ID: 16307499
    [TBL] [Abstract][Full Text] [Related]  

  • 10. European countries with small populations can obtain low prices for drugs: Lithuania as a case history.
    Garuoliene K; Godman B; Gulbinovič J; Wettermark B; Haycox A
    Expert Rev Pharmacoecon Outcomes Res; 2011 Jun; 11(3):343-9. PubMed ID: 21671703
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Review article: the clinical pharmacology of proton pump inhibitors.
    Sachs G; Shin JM; Howden CW
    Aliment Pharmacol Ther; 2006 Jun; 23 Suppl 2():2-8. PubMed ID: 16700898
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of proton pump inhibitors and risk of fragility hip fracture in a Mediterranean region.
    Reyes C; Formiga F; Coderch M; Hoyo J; Ferriz G; Casanovas J; Monteserín R; Brotons C; Rojas M; Moral I
    Bone; 2013 Feb; 52(2):557-61. PubMed ID: 23023097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inappropriate prescribing of proton pump inhibitors in hospitalized patients.
    Reid M; Keniston A; Heller JC; Miller M; Medvedev S; Albert RK
    J Hosp Med; 2012; 7(5):421-5. PubMed ID: 22190465
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Persistence and adherence to proton pump inhibitors in daily clinical practice.
    Van Soest EM; Siersema PD; Dieleman JP; Sturkenboom MC; Kuipers EJ
    Aliment Pharmacol Ther; 2006 Jul; 24(2):377-85. PubMed ID: 16842465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The early effect of proton pump inhibitor therapy on the accuracy of the 13C-urea breath test.
    Mana F; Van Laer W; Bossuyt A; Urbain D
    Dig Liver Dis; 2005 Jan; 37(1):28-32. PubMed ID: 15702856
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endoscopic and histopathologic gastric changes in chronic users of proton-pump inhibitors.
    Camilo SM; Almeida ÉC; Miranzi BA; Silva JC; Nomelini RS; Etchebehere RM
    Arq Gastroenterol; 2015; 52(1):59-64. PubMed ID: 26017085
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Policies to enhance the efficiency of prescribing in the Spanish Catalan region: impact and future direction.
    Coma A; Zara C; Godman B; Agustí A; Diogène E; Wettermark B; Haycox A
    Expert Rev Pharmacoecon Outcomes Res; 2009 Dec; 9(6):569-81. PubMed ID: 19941434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oesophageal and gastric pH profiles in patients with gastro-oesophageal reflux disease and Barrett's oesophagus treated with proton pump inhibitors.
    Gerson LB; Boparai V; Ullah N; Triadafilopoulos G
    Aliment Pharmacol Ther; 2004 Sep; 20(6):637-43. PubMed ID: 15352912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Meta-analysis: proton-pump inhibition in high-risk patients with acute peptic ulcer bleeding.
    Bardou M; Toubouti Y; Benhaberou-Brun D; Rahme E; Barkun AN
    Aliment Pharmacol Ther; 2005 Mar; 21(6):677-86. PubMed ID: 15771753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proton pump inhibitors as a treatment method for type II diabetes.
    Mefford IN; Wade EU
    Med Hypotheses; 2009 Jul; 73(1):29-32. PubMed ID: 19304401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.